London Calling: Flagship Expands in U.K. to Build AI-Native Platform Companies
Flagship Pioneering, which for more than 25 years has created and nurtured startups—most notably mRNA vaccine giant Moderna—from Cambridge, MA, has launched its first dedicated company creation unit outside of the U.S. with an initial commitment of £100 million ($131.66 million) that the venture capital giant expects to quintuple in coming years.
The new London-based Flagship Origination Lab U.K. has been established to conceive, test, fund, and build artificial intelligence (AI)-native platform companies that advance human and planetary health and other frontiers of science and technology.
Flagship said the U.K. Lab will operate as part of Flagship Labs, the company’s innovation foundry, with the goal of creating a locally rooted company-creation ecosystem in the United Kingdom that connects to Flagship’s broader global ecosystem, including business units and:
- Pioneering Intelligence, Flagship’s AI and machine learning innovation effort designed to originate new companies by harnessing advances in computation integrated with a variety of scientific domains. Pioneering Intelligence was launched in 2023.
- Pioneering Medicines, Flagship’s in-house drug development unit founded in 2020. Pioneering Medicines explores and identifies new product concepts, then works jointly with Flagship’s companies to form integrated teams that advance new treatments through discovery and early clinical development. Medicines also partners with external collaborators.
“I think this announcement by Flagship is a testament to the quality of British life sciences research and the investment will be welcomed in the U.K.,” Tim Harris, PhD, DSc, a molecular biologist, biochemist, and geneticist who is an operating partner with SV Health Investors specializing in work with therapeutics startups, told GEN.

“Labs and people turn ideas into companies so I look forward to seeing some new ones come out of this initiative from the Flagship Pioneering team,” Harris added.
Founded in 1999, Flagship Pioneering has founded and nurtured more than 120 companies—between six and eight each year—employing more than 9,000 people. Thirteen Flagship Pioneering-launched companies have gone public through initial public offerings (IPOs) since 2013.
In London, Flagship expects to recruit and train an initial team of approximately 50 U.K.-based scientist-entrepreneurs and operators for the new Origination Lab, U.K., which will build on three years of experience partnering and conducting R&D across the kingdom.
Flagship is not the first U.S. VC firm to establish an outpost in the U.K. for nurturing startups from the kingdom: Harris noted that SV venture capitalists led by Kate Bingham, managing partner and co-leader of SV’s biotech franchise, have been creating and investing in U.K. and U.S. startups for many years.
Flagship’s new Origination Lab adds to the capital available, creating further opportunities for early-stage companies, Harris added.
‘Natural home’
“The U.K. is a natural home for AI and life sciences companies, and we want to see more new businesses across these sectors turning cutting-edge research and technology into new jobs and economic growth,” Chris McDonald, a chemical engineer and member of the U.K. Parliament (Labour Party) who is the kingdom’s Minister for Science, Innovation and Investment, said in a statement. “This new commitment from Flagship Pioneering will kickstart companies of the future in the U.K., who will take breakthroughs in AI and life sciences to the rest of the world and deliver innovations that can save lives.”
Flagship’s announcement comes weeks after AbbVie announced plans to expand its R&D facility in Oxford, U.K., as part of a £120 million ($158 million) investment into life sciences activity within the kingdom. AbbVie plans to expand its existing Oxford campus by constructing a new 12,000-square-foot site focused on research in immunology, neuroscience, and oncology.
However, since last year two other biopharma giants, AstraZeneca and Merck & Co., have dropped plans for large facilities within the U.K. AstraZeneca cited government funding reductions in halting plans for a £450 million vaccine manufacturing center in Merseyside.
Merck aborted plans for an R&D site set to employ 800 (including 180 researchers) at Belgrove House near King’s Cross in London, citing what it called high rebate clawback rates for voluntary and statutory medicines by the NHS, and insufficient government investment in life sciences, reflected in a decline from second to eighth since 2017 in SCI’s global foreign direct investment ranking in life sciences.
Flagship began expanding beyond the U.S. in 2023 when it opened offices in London and in Singapore. Since opening the London hub by signing a Memorandum of Understanding with the U.K. Government, Flagship has announced an agreement with Cambridge University Health Partners and the Milner Therapeutics Institute to collaborate to jointly advance breakthrough scientific research and technologies.
Also from the London hub, Flagship has launched its first transatlantic company, Quotient Therapeutics; accelerated first-in-category clinical trials across the U.K. by Flagship-founded companies such as Generate:Biomedicines; and developed numerous strategic partnerships across academia, data, and regulatory innovation.
Generate was founded in 2018 as a Flagship Pioneering company, and emerged from stealth operations during the COVID-19 pandemic two years later, when it announced that it had built a portfolio of therapeutic candidates for neutralizing SARS-CoV‑2, including antibodies and peptides targeting multiple epitopes on the spike protein peptide, in less than 17 days.
The biologics developer was an early comer applying AI-based approaches to rationally design sequence, structure, and function for protein therapeutics. In February, Generate went public on the Nasdaq Global Market through a $400 million IPO that generated $369.3 million in net proceeds.
‘New chapter’
“Today marks the beginning of a new chapter in Flagship’s relationship with the U.K.,” declared Noubar Afeyan, PhD, Flagship Pioneering’s founder and CEO. “Over the past three years, we have seen firsthand the extraordinary depth of scientific imagination, talent, and ambition across the country. With our £100 million initial commitment, which we anticipate scaling through partnership to attract an additional £500 million [$658.6 million], we are now making a long-term commitment to build on that foundation.”
Afeyan announced the new U.K. Lab on Monday at a conference of the U.K.’s Drug Information Association (DIA) and Medicines and Healthcare products Regulatory Agency (MHRA). The DIA-MHRA Global Summit is set to conclude Tuesday during London Life Sciences Week.
“Since first opening our London office three years ago, we’ve been impressed by the talent, imagination, and ambition that make the U.K. a leader in our field—and we are excited about the groundbreaking ventures that will come from combining our unique Flagship model with the U.K.’s distinct strengths,” Afeyan said in a LinkedIn post.
Added Avak Kahvejian, PhD, general partner, Flagship Pioneering and president of its internal innovation foundry and company-creation unit Flagship Labs: “We have developed company origination into a discipline, one led by teams of scientist-entrepreneurs who begin with bold questions about what could be possible.”
“As we extend that capability globally, the U.K. was a clear and deliberate choice for our first expansion. Its exceptional science base, clinical-trial infrastructure, genomics and health-data assets, agile regulatory environment, and brilliant scientists and entrepreneurs create a powerful foundation for innovation,” Kahvejian stated.
The post London Calling: Flagship Expands in U.K. to Build AI-Native Platform Companies appeared first on GEN - Genetic Engineering and Biotechnology News.
Apa Reaksi Anda?
Suka
0
Kurang Suka
0
Setuju
0
Tidak Setuju
0
Bagus
0
Berguna
0
Hebat
0
